This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
Ball G, et al. Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada. PharmacoEconomics-Open : 29 May 2017. Available from: URL: http://dx.doi.org/10.1007/s41669-017-0030-7
Rights and permissions
About this article
Cite this article
Bevacizumab not cost effective for ovarian cancer in Canada. PharmacoEcon Outcomes News 780, 11 (2017). https://doi.org/10.1007/s40274-017-4063-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4063-z